JW Therapeutics interim revenue up 4.7% on Carteyva sales
JW Therapeutics interim revenue rose 4.7% on Carteyva sales, according to TradingView News.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.